Navigation Links
Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Date:11/10/2008

d ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB- 509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the it'
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
2. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
5. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
6. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
8. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
9. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
10. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
11. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... reveal critical evidence, as well as an identity, with ... University that detects trace amounts of explosives, drugs or ... new technology also can distinguish between overlapping fingerprints left ... optical forensic methods. , A team led by R. ...
... Brazil, Sept. 23 A bill designed to,strengthen ... by,the U.S. Senate Foreign Relations Committee, is a ... the United States to promote the production,and use ... the,Brazilian Sugarcane Industry Association (UNICA)., "It shows ...
... 23 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... the Company,s pressure cycling technology ("PCT") was ... Fifth International Conference on,High Pressure Bioscience and ... San Diego, CA. The HPBB Conference was ...
Cached Biology Technology:Fingerprints provide clues to more than just identity 2New Bill to Expand Promotion of Biofuels Is a Welcome Boost for U.S.-Brazil Relations According to Brazilian Sugarcane Industry 2New Bill to Expand Promotion of Biofuels Is a Welcome Boost for U.S.-Brazil Relations According to Brazilian Sugarcane Industry 3Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting 2Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting 3Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending 'PCT Shredder' at the Meeting 4
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... REDWOOD CITY, Calif., Oct. 28 , WHAT: ... speak at the Dallas SecureWorld Expo in the Industry ... "Protecting the User-Led Aspect of Endpoint Security," Fulton will ... caused by end users. He will further examine how ...
... emerging for how important it is for pregnant women to ... day seem to have children who are less likely to ... from the Sahlgrenska Academy at the University of Gothenburg, ... Linkping University, which is conducting a population study called ABIS ...
... Olympus, a precision technology leader creating innovative opto-digital ... today announced the availability of VisiGlide 1 , its ... Terumo Corporation 2 to facilitate ERCP procedures ... of the bile and pancreatic ducts, the new 0.025 ...
Cached Biology News:DigitalPersona to Speak at Dallas SecureWorld Expo 2Vegetables can protect unborn child against diabetes 2Olympus introduces the VisiGlide, a single-use guidewire 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An N-nitroso-containing ... nitric oxide donor in pancreatic islets. ... Causes DNA alkylation and DNA strand ... ≥95% by HPLC. Soluble in H ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: